Amgen announced Otezla is now available in the U.S. for pediatric use. Earlier this year, the U.S. FDA approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg and are candidates for phototherapy or systemic therapy. There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says
- Ardelyx appoints Foster as Chief Commercial Officer
- Disney, CVS headline busy day of earnings: Wednesday Buzz
- Disney, Airbnb dip despite quarterly beats: Morning Buzz
- Arm upgraded, Molson Coors downgraded: Wall Street’s top analyst calls